XOMA
NASDAQXOMA Royalty Corporation
Price$42.25+16.25 (+62.50%)
2026-03-062026-06-09
News · 26 weeks50+22%
2025-12-142026-06-07
Mix3690d
- Insider18(50%)
- SEC Filings13(36%)
- Earnings2(6%)
- M&A2(6%)
- Other1(3%)
Latest news
25 items- INSIDERDirector Wyszomierski Jack L was granted 3,586 shares, increasing direct ownership by 17% to 25,116 units (SEC Form 4)4 - XOMA Royalty Corp (0000791908) (Issuer)
- INSIDERDirector Limber Joseph M was granted 3,586 shares, increasing direct ownership by 39% to 12,820 units (SEC Form 4)4 - XOMA Royalty Corp (0000791908) (Issuer)
- INSIDERDirector Hernday Natasha was granted 3,586 shares, increasing direct ownership by 40% to 12,592 units (SEC Form 4)4 - XOMA Royalty Corp (0000791908) (Issuer)
- INSIDERDirector Perry Matthew D was granted 3,586 shares, increasing direct ownership by 15% to 27,426 units (SEC Form 4)4 - XOMA Royalty Corp (0000791908) (Issuer)
- INSIDERDirector Franklin Heather L was granted 3,586 shares, increasing direct ownership by 60% to 9,557 units (SEC Form 4)4 - XOMA Royalty Corp (0000791908) (Issuer)
- INSIDERDirector Kosacz Barbara was granted 3,586 shares, increasing direct ownership by 60% to 9,557 units (SEC Form 4)4 - XOMA Royalty Corp (0000791908) (Issuer)
- SECSEC Form 425 filed by XOMA Royalty Corporation425 - XOMA Royalty Corp (0000791908) (Subject)
- SECSEC Form 8-K filed by XOMA Royalty Corporation8-K - XOMA Royalty Corp (0000791908) (Filer)
- INSIDERLarge owner Bvf Partners L P/Il converted options into 5,003,000 shares (SEC Form 4)4 - XOMA Royalty Corp (0000791908) (Issuer)
- SECSEC Form DEFA14A filed by XOMA Royalty CorporationDEFA14A - XOMA Royalty Corp (0000791908) (Filer)
- SECSEC Form 8-K filed by XOMA Royalty Corporation8-K - XOMA Royalty Corp (0000791908) (Filer)
- SECSEC Form 10-Q filed by XOMA Royalty Corporation10-Q - XOMA Royalty Corp (0000791908) (Filer)
- SECAmendment: XOMA Royalty Corporation filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - XOMA Royalty Corp (0000791908) (Filer)
- SECSEC Form DEFA14A filed by XOMA Royalty CorporationDEFA14A - XOMA Royalty Corp (0000791908) (Filer)
- SECSEC Form 8-K filed by XOMA Royalty Corporation8-K - XOMA Royalty Corp (0000791908) (Filer)
- PRLigand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty AggregatorTransaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.501 and expects the transaction to be accretive by $1.50 per share to adjusted EPS in 20272 Ligand to hold investor call at 8:00 a.m. ET today JUPITER, Fla. and EMERYVILLE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporate
- INSIDERSEC Form 4 filed by Sitko Bradley4 - XOMA Royalty Corp (0000791908) (Issuer)
- INSIDERSEC Form 4 filed by Hughes Owen4 - XOMA Royalty Corp (0000791908) (Issuer)
- INSIDERSEC Form 4 filed by Trigilio Jeffrey4 - XOMA Royalty Corp (0000791908) (Issuer)
- INSIDERSEC Form 4 filed by Montano Maricel Perea4 - XOMA Royalty Corp (0000791908) (Issuer)
- INSIDERSEC Form 4 filed by Trigilio Jeffrey4 - XOMA Royalty Corp (0000791908) (Issuer)
- INSIDERSEC Form 4 filed by Limber Joseph M4 - XOMA Royalty Corp (0000791908) (Issuer)
- SECSEC Form DEFA14A filed by XOMA Royalty CorporationDEFA14A - XOMA Royalty Corp (0000791908) (Filer)
- SECSEC Form DEF 14A filed by XOMA Royalty CorporationDEF 14A - XOMA Royalty Corp (0000791908) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by XOMA Royalty CorporationSCHEDULE 13G/A - XOMA Royalty Corp (0000791908) (Subject)
XOMA FAQ
7 questionsWhat does XOMA Royalty Corporation do?
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy; XMetA, an insulin receptor-activating antibody to provide long-acting reduction...Where does XOMA stock trade?
XOMA Royalty Corporation (XOMA) is listed on NASDAQ.What sector and industry is XOMA in?
XOMA Royalty Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did XOMA Royalty Corporation go public?
XOMA Royalty Corporation (XOMA) completed its IPO in 1986.What are analysts saying about XOMA?
XOMA Royalty Corporation has had 7 recent analyst actions on file. The most recent action was from The Benchmark Company: Buy with a $3500.00 price target on 2025-04-17. Recent price targets range from $2200.00 to $4000.00.What companies are similar to XOMA?
Notable peers in the same industry include RZLT (Rezolute Inc.), PALI (Palisade Bio Inc.), YTEN (Yield10 Bioscience Inc.). Compare XOMA side-by-side with any of them on Quantisnow.How can I track XOMA on Quantisnow?
Quantisnow aggregates XOMA Royalty Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XOMA to receive live email and push alerts on every new disclosure.